Your Search Returned 500 tagged news reports
The prices of drugs are expected to increase by around 10 percent, said chairman of the East Java branch of GP Farmasi, Paulus Totok Lucida, on Tuesday. It was unlikely that the fuel hikes would influence the prices of generic drugs, however, he said.
A Supreme Court decision Monday allowing federal regulators to continue challenging "pay-for-delay" deals between pharmaceutical companies and generic drug makers on anti-competitive grounds was greeted with dismay by industry observers after the
Indian drug major Sun Pharmaceutical Industries last week agreed to pay $550 million to New York-based Pfizer as part of an out-of-court settlement of the Protonix patent infringement lawsuit. Assuming the out-of-court settlement had not taken place
EDT June 17, 2013 Justices rule that settlements of patent lawsuits are often anti-competitive under federal law, even though they could benefit consumers in some cases. Profit-sharing deals between brand-name and generic drug companies that preserve
The Supreme Court says states cannot require would-be voters to prove they are U.S. citizens before using a federal registration system designed to make signing up easier. The Supreme Court says prosecutor can use a person's silence against them in
In Weeks the Alabama Supreme Court had acted precipitously, without oral argument discussing the above policy issues. Fortunately, it seems to have realized that there is more to this theory than liability uber alles .
We have taken adequate measures to ensure that those shortcomings will not trouble us in future," Ranbaxy Laboratories CEO and managing director Arun Sawhney told PTI in an interview. He said Ranbaxy has invested more than $300 million in recent
That excess spending was driven in large part by pharmaceutical companies' efforts to delay generic drug patents and undermine competition that would lower health care costs. Researchers compared drugs used by veterans who get VA benefits against
Daiichi Sankyo believed it had scored a coup in 2008 when it outbid rivals to buy Indian generics giant Ranbaxy for $4.6 billion but its foray into the high-growth copycat drugs arena has brought the Japanese drugmaker only pain. Last month, Ranbaxy
Ganesh Nayak Pharma major Zydus Cadila believes that despite the recent Ranbaxy episode involving adulterated generic drugs, the pharma industry does not need more domestic and international regulation. According to Chief Operating Officer Ganesh